Precise Patient Intervention. Improved Outcomes.

Advancing peripheral edema monitoring from subjective and manual assessment to CardioVere's objective digital measurement for consistency and reliability.

CardioVere
CardioVere leverages proven, patented molecular chemical imaging technology developed by ChemImage. The technology uses light, filters, and optics paired with our proprietary algorithms and software enabling the user to see the unseen.

6.2 M

adults in the U.S. have been diagnosed with Heart Failure
CardioVere enables more precise monitoring of patients to ensure quality of care.

46 %

growth rate in heart failure diagnosis with an estimated 8M people in the U.S. by 2030
Heart failure will continue to be a cost burden. CardioVere helps to more effectively manage patients based on edema levels, a key indicator of heart failure status.

1 in 4

heart failure patients will be readmitted to the hospital within 30 days of discharge
CardioVere empowers patients to monitor their edema levels and communicate with providers, thus minimizing emergency visits and readmissions.

$70B

is the projected annual cost of heart failure by 2030
The CardioVerification Index from CardioVere enables consistent, objective, digital measurement of edema level, allowing providers to intervene before a patient goes to the hospital. Effective measurements in the hospital may also reduce length of stay.

CardioVere Applications

Lorem ipsum dolor sit amet, consectetur adipiscing elit. 
Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Seeking Partnership Opportunities with Global MedTech Leaders